Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-11
2005-10-11
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212080, C514S218000, C540S492000, C540S524000, C540S527000
Reexamination Certificate
active
06953788
ABSTRACT:
The present invention relates to certain novel 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase. Pharmaceutical compositions containing said compounds as well as methods of treating various disease states responding to inhibition of matrix metalloproteinase are also claimed herein.
REFERENCES:
patent: 4599361 (1986-07-01), Dickens et al.
patent: 4681966 (1987-07-01), Donald et al.
patent: 4771038 (1988-09-01), Wolanin et al.
patent: 4885283 (1989-12-01), Broadhurst et al.
patent: 4935404 (1990-06-01), Hunter et al.
patent: 5238932 (1993-08-01), Flynn et al.
patent: 5239078 (1993-08-01), Galardy et al.
patent: 5252560 (1993-10-01), Myers et al.
patent: 5300501 (1994-04-01), Porter et al.
patent: 5304549 (1994-04-01), Broadhurst et al.
patent: 5310763 (1994-05-01), Campion et al.
patent: 5362750 (1994-11-01), Rosini et al.
patent: 5366973 (1994-11-01), Flynn et al.
patent: 5389628 (1995-02-01), Flynn et al.
patent: 5420271 (1995-05-01), Warshawsky et al.
patent: 5424425 (1995-06-01), Flynn et al.
patent: 5428158 (1995-06-01), Warshawsky et al.
patent: 5430145 (1995-07-01), Flynn et al.
patent: 5455242 (1995-10-01), Warshawsky et al.
patent: 5457196 (1995-10-01), Warshawsky et al.
patent: 5504212 (1996-04-01), de Solmes et al.
patent: 0236872 (1987-09-01), None
patent: 0489579 (1992-06-01), None
patent: 0534363 (1993-03-01), None
patent: 0621270 (1994-10-01), None
patent: 9606890 (1988-09-01), None
patent: 9513289 (1995-05-01), None
patent: 9611209 (1996-04-01), None
patent: 9629313 (1996-09-01), None
patent: 9635687 (1996-11-01), None
patent: 9635711 (1996-11-01), None
patent: 9635714 (1996-11-01), None
patent: 9636227 (1996-11-01), None
patent: 9665712 (1996-11-01), None
patent: 9712861 (1997-04-01), None
patent: 9712902 (1997-04-01), None
patent: 9717088 (1997-05-01), None
patent: 9719075 (1997-05-01), None
Greenwald, Annals of the New York Academy of Sciences 878:413-419 (1999).
McCachren, S.S.Arthritis Rheum.34, pp 1085-1093 (1991).
Emonard, H. et al,Cell Molec. Biol.36, pp 131-153 (1990).
Birkedal-Hansen, H.,J. Oral Pathol.17, pp 445-451 (1988).
Matrisian, L.M.,Trends Genet.6, pp 121-125 (1990).
Murphy, G.J.P. et al,FEBS Lett.289, pp 4-7 (1991.
Matrisian, L.M.,Bioessays14, pp 455-463 (1992).
Swhwartz, G.K. et al,Cancer73, pp 22-27 (1994).
Bernhard, E.J. et al,Proc. Natl. Acad. Sci.91, pp 4293-4597 (1994).
Zucker, S. et al, Cancer Res. 53, pp 140-146 (1993).
Chirivi, R.G.S. et al,Int. J. Cancer58, pp 460-464 (1994).
Montgomery, A.M.P. et al,Cancer Res.54, pp 5467-5473 (1994).
Hasty, K.A. et al,Arthr. Rheum.33, pp 388-397 (1990).
Murphy, G. et al,Biochem. J.248, pp 265-268 (1987).
Gearing, A.J.H. et al,Nature370, pp 555-557 (1994).
Mohler, K.M. et al,Nature370, pp 218-220 (1994).
McGreehan, G.M. et al,Nature370, pp 558-561 (1994).
Wahl, R.C. et al,Annual Reports in Medicinal Chemistry25, pp 177-184 (1990).
Hennney, A.m., et al,Proc. Natl. Acad. Sci.88, pp 8154-8158 (1991).
Burns, F.R. et al,Invest. Opthalmol. and Visual Sci.30, No. 7 pp 1569-1575 (1989).
Overall, C.M. et al,J. Periodontal Res.22, pp 81-88 (1987).
Miyazaki, K. et al,Nature362, pp 839-841 (1993).
Beckett, R.P. et al, “Recent advances in matrix metalloproteinase inhibitor research”DDTvol. 1, No. 1, Jan., 1996, pp 16-26.
Blanchard et al, “Reevaluation of the Absorption of Carbenoxolone Using an In Situ Rat Intestinal Techinque”,Journ. Pharmaceutical Sci.,vol. 79, No. 5, May, 1990 pp 411-414.
Davies, B. et al, “A Synthetic Matrix Metalloproteinase Inhibitor Decreases Tomor Burden . . . ”,Cancer Research53, May 1, 1993, pp 2087-2091.
Hodgson, John, “Remodeling MMPIs”,Bio/Technologyvol. 13, Jun. 1995 pp 554-557.
Chapman, K.T., “Inhibition of Matrix Metalloproteinases . . . ”, J. Med. Chem. 1993, 36, pp 4293-4301.
Beeley N.R.A, “Inhibitors of Matrix Metalloproteinases (MMP's)”, Curr. Opin, Ther. Patents (1994) 4(1), pp 7-16.
Baxter, Andrew D. et al, “A Novel Series of Matrix Metalloproteinase Inhibitors for the Treatment of Inflammatory Disorders”, Bioorganic & Medicinal Chem. Letters, vol. 7, No. 7 pp 897-902, (1997).
CA, Issue 3, pp 16, 126:60361y (1997).
Derwent Abstract 96-035866, Week 9604, WPI Database XP 002046217.
Burkholder, E.A., Bioorg Med Chem Lett, vol. 3, No. 2, 1993, p 231-234, XP002046216.
Beight Douglas W.
Burkhart Joseph P.
Dharanipragada Ramalinga M.
Flynn Gary A.
Janusz Michael J.
Aventis Pharmaceuticals Inc.
Kifle Bruck
Synnestvedt & Lechner LLP
LandOfFree
3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3462033